PBYI SCHEDULE 13G: SEC filing

American Century Investment Management and affiliated entities

Filed with the SEC on · accession 0000052388-26-000503

PBYI filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 16, 2026. American Century Investment Management and affiliated entities filed a Schedule 13G disclosing beneficial ownership of approximately 5.1-5.3% of Puma Biotechnology's common stock as of September 30, 2026. The stock moved -5.5% by the first close after the filing.

Summary of the filing

American Century Investment Management and affiliated entities filed a Schedule 13G disclosing beneficial ownership of approximately 5.1-5.3% of Puma Biotechnology's common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b).

Key details

Shares beneficially owned by American Century ETF Trust$2.6M
Shares beneficially owned by American Century Investment Management, Inc.$2.7M
Shares beneficially owned by American Century Companies, Inc.$2.7M
Shares beneficially owned by Stowers Institute for Medical Research$2.7M
Issuer/subject companyPuma Biotechnology, Inc.
Beneficial owner (5.1%)American Century ETF Trust
Beneficial owner (5.3%), investment adviserAmerican Century Investment Management, Inc.
Beneficial owner (5.3%), parent of acimAmerican Century Companies, Inc.
Beneficial owner (5.3%), control entity of accStowers Institute for Medical Research
Senior vice presidentJohn Pak
Authorized signerJoselyn Verschelden

How PBYI stock reacted

Close before

$7.77

Nov 13, 2026

First close after

-5.53%

$7.34

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for PBYI, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PBYI?

Click here

Frequently asked questions

What did PBYI file with the SEC on Nov 16, 2026?

PBYI filed a SCHEDULE 13G (SEC filing). American Century Investment Management and affiliated entities filed a Schedule 13G disclosing beneficial ownership of approximately 5.1-5.3% of Puma Biotechnology's common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b).

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did PBYI stock react to this filing?

PBYI closed at $7.77 before the filing and $7.34 on Nov 16, 2026 (-5.53%).

Other PBYI SEC filings

Get alerts when PBYI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days